Evaluation and Comparison of a Novel Dentrifice Formulation on Plaque Removal

Protegera, Inc.1 site in 1 country82 target enrollmentJanuary 30, 2023

ConditionsDental Plaque

InterventionsProtegera™ toothpaste (NaF)Crest™ Cavity Protection toothpaste (NaF)

DrugsProtegera™ toothpaste (NaF)Crest™ Cavity Protection toothpaste (NaF)

Overview

Phase: Early Phase 1
Intervention: Protegera™ toothpaste (NaF)
Conditions: Dental Plaque
Sponsor: Protegera, Inc.
Enrollment: 82
Locations: 1
Primary Endpoint: Changes in oral soft or hard tissues
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

To evaluate and compare plaque removal efficacy and safety of a novel dentifrice formulation immediately after the first supervised use and following one week of twice, daily use at home.

Detailed Description

Study participants brushed their teeth for one minute, two times daily, for seven days. Participants who met study entry criteria were randomized to either the test (Protegera™) or control (Crest™ Cavity Protection) toothpaste, and each were given the same straight, soft bristled toothbrush to use throughout the study. On Day 1, participants were given an oral exam, and a pre-brushing plaque score was recorded. Participants then brushed their teeth for one minute under supervision, and a post-brushing plaque score was recorded. On Day 7, participants were given an oral exam, and a pre-brushing plaque score was recorded. Participants then brushed their teeth for one minute under supervision, and a post-brushing plaque score was recorded.

Registry

clinicaltrials.gov

Start Date

January 30, 2023

End Date

February 23, 2023

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Protegera, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Have been males and females aged 18 to 69, in good general health.
•Have read and signed an Informed Consent Form.
•Have been in good health based on medical history review by the Principal Investigator.
•Have had a minimum of 18 natural teeth with scorable facial and lingual surfaces. Teeth that were grossly carious, orthodontically banded, restorations such as crowns, veneers or implants, exhibit general cervical abrasion and/or enamel abrasion, or third molars were not included in the tooth count.
•(If female of child bearing age) have been using an established method of birth control (systemic contraceptives such as birth control pills, injectable contraceptive or patch contraceptives, partner with vasectomy, condom with additional spermicide, IUD or abstinence).
•Have had a mean full-mouth pre-brushing plaque score (Soparkar Modification1 of the Turesky Modification2 of the plaque index of Quigley and Hein.3) of ≥ 2.00 at the baseline visit.
•Have agreed not to have a dental prophylaxis or any other elective, non-emergency dental procedures (other than those provided during the study) any time during the 7-day study.
•Have been willing to refrain from all oral hygiene procedures (including chewing gum) for 24 hrs. and refrained from eating, drinking and smoking for approximately 2 hours prior to Visits 1 \&
•Have agreed to refrain from use of all oral hygiene products (i.e., floss, mouthwash, etc.), other than the toothbrush and toothpaste supplied, for the duration of the 7-day study.
•Have agreed to comply with the conditions and schedule of the study.

Exclusion Criteria

•Had any known allergies or sensitivities to marketed dentifrice or oral hygiene products.
•Had any physical limitations or restrictions which might preclude normal tooth brushing.
•Had existing serious medical condition or transmittable disease as determined after review of the medical history form. These will include but not be limited to: active hepatitis, tuberculosis, AIDS, asthma, bleeding disorder, diabetes, cirrhosis, leukemia, renal disease, sarcoidosis, vascular disease, thrush, or leukoplakia.
•Self-reported as pregnant or nursing female.
•Required antibiotic therapy within 30-days prior to study treatment.
•Had a history of adverse effects, oral soft or hard tissue sensitivity, to any ingredient in the test materials.
•Had received therapy with any medications, currently or within the last 30 days, which might interfere with the outcome of the study by affecting tissue condition, or salivation, particularly chronic therapy or long-term use, as determined by the investigator.
•Had severe periodontal disease or being actively treated for periodontal disease.
•Had fixed or removable orthodontic appliances, bridges, peri/oral piercings, or removable partial dentures.
•Had significant oral soft tissue pathology based on a visual examination baseline.